#monarch3 search results
DONATING ALL MY MUSIC STREAMING MONEY TO ANY BLM FUNDRAISERS I COME ACROSS ❤️ (link more below) #MONARCH3
1. #MONARCH3 OS update, Ph3, AI Vs #abemaciclib + AI in HR+ve, mBC - Abema improved OS (67.1 mos vs 54.5 mos, HR: 0.754) but not stat. significant (final data in 2023) - Pts with visceral disease did better - Cross trial OS comparison: #Ribociclib +ve & #Palbociclib -ve 2/6
👀 on @OncJournal ➡️ #Safety analysis of #MONARCH2 & #MONARCH3 & management of abemaciclib-associated adverse events ➡️ PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities #Oncoalert theoncologist.onlinelibrary.wiley.com/doi/full/10.10…
The @OncoAlert 🚨WrapUp for Day1⃣of #ESMO22 #TROPiCS02 🌴 #MONARCH3 🦋 Best, @weoncologists @ErikaHamilton9 @DrChoueiri @TiansterZhang @neerajaiims @ERPlimackMD @drenriquegrande @CancerCareMASCC @hoperugo @matteolambe @NicoleKuderer @prat_aleix @DrRBarroso @kevinpunie
#MONARCH3 Final OS data (median follow up of 8.1 years) OS: 66.8 vs 53.7 months Was not statistically significant even with 13.1 months 🔺 different! To control Arm clinical meaningful improvement ✔️ Is it because of small sample size? 2 ndry endpoint? @OncoAlert #SABCS23
Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain) @OncoAlert @myESMO
Dr. Goetz presents IA2 #MONARCH3 OS for AI +/- abema: OS - 54.5 mo vs 67.1 months, p value not signif. OS visceral Mets: ⬆️ 16.3 months w/ abema but again not statistically signif yet. Updated PFS: 14.8 to 29 mo w/ abema Final OS will be reported next year #bcsm #ESMO22
Also true in breast oncology. #MONARCH3 trial of 1L ET+/-abema for metastatic breast cancer. Doubling of PFS, major numerical OS benefit with abema— yet with a clear crossing of the curves. Important to recognize frail patients, which may do well (if not better) with monotherapy.
Same phenomenon occurs in #MARIPOSA as noted by Dr. @harpreet_md in #FLAURA2 - its minor but perhaps early increase toxicity with intensified treatment is bad for some patients outcome? #WCLC2025 #lcsm
Second interim analysis of OS data from #MONARCH3 at #ESMO22: numerical longer OS with abemaciclib in HR+,HER-neg #breastcancer, that does not cross the statistical significant threshold as per statistical design. Final OS analysis in 2023 @OncoAlert
#SABCS23 in pillole, secondo @ArmandOrlandi #breastcancer @matteolambe @BianchiniGP #MONARCH3 #NATALEE #monarchE #INAVO120
やっぱりTHIE AUDIOはあたたかい。 凄くクリアで解像度高いのに音の繋がりが滑らかでぬくぬく。 低音域は主張しすぎておらず全然支配的ではないのにも関わらず、分離と解像度のお陰でベースの弦の揺れまで聴き取れる。 高音域も伸びる伸びるで聴いてて楽しい。 #THIEAUDIO #Monarch3
2. #MONARCH3 8 year follow-up: #Abemaciclib + AI vs AI in HR+ mBC 1L: - ITT showed ⬆️of 13.1mos OS with Abema (66.8 vs 53.7 mos) BUT⛔️ statistical significant (HR: 0.804; 95% CI, 0.637-1.015; p=0.0664) 🤔 Now what? - Ribo > Abema > Palbo? 3/6
MONARCH3: Final OS analysis (median fu 8 years) 66.8 vs 53.7 months Not statistically significant but clinically meaningful 🔺13.1 months #bcsm #SABCS23 @OncoAlert
Also true in breast oncology. #MONARCH3 trial of 1L ET+/-abema for metastatic breast cancer. Doubling of PFS, major numerical OS benefit with abema— yet with a clear crossing of the curves. Important to recognize frail patients, which may do well (if not better) with monotherapy.
Same phenomenon occurs in #MARIPOSA as noted by Dr. @harpreet_md in #FLAURA2 - its minor but perhaps early increase toxicity with intensified treatment is bad for some patients outcome? #WCLC2025 #lcsm
*NEW EPISODE* - Metastatic HR +ve Breast Cancer CDK4/6 changed the #breastcancer landscape. With more trials underway next generationxt-gen of drugs on the horizon, we revisit where it all started. #oncology #MONARCH3 #PALOMA2 #MONALEESA2 open.spotify.com/episode/7e2HO2…
やっぱりTHIE AUDIOはあたたかい。 凄くクリアで解像度高いのに音の繋がりが滑らかでぬくぬく。 低音域は主張しすぎておらず全然支配的ではないのにも関わらず、分離と解像度のお陰でベースの弦の揺れまで聴き取れる。 高音域も伸びる伸びるで聴いてて楽しい。 #THIEAUDIO #Monarch3
I think most patients would have an easy job picking which curve they wanted to be on. #Monarch3 #bcsm
MONARCH 3 final OS results. Statistically negative (p=0.06), but hard to argue that 13.1 months delta in OS does not denote a clinical benefit. annalsofoncology.org/article/S0923-…
¡Consulta las opiniones de nuestro panel de expertos sobre el estudio Monarch 3: Final OS Data! #monarch3 #estudio #oncología @LillyES elmedicointeractivo.com/monarch-3-fina…
Check out this podcast to hear updates from @JAMouabbi on #SABCS23! Dr. Mouabbi delves into the presentations on the #HER2CLIMB02, #MONARCH3, and #INAVO trials and explains their potentials to impact the #BreastCancer treatment landscape. Listen here! oncdata.com/news/highlight…
#SABCS23 | Quale valore assumono i nuovi dati del #MONARCH3 rispetto alla domanda clinica e nella storia della patologia? Lo abbiamo chiesto ad @ALEDIGNUS12. @UniAvogadro oncoinfo.it/congressi/il-v…
oncoinfo.it
Il viaggio del trial MONARCH 3 - OncoInfo
Quale valore assumono i nuovi dati rispetto alla domanda clinica e nella storia della patologia? “Dr. Taxi” viaggia per le strade di San Antonio, in Texas, durante il congresso SABCS 2023.
🌟Prof Patrick Neven shares groundbreaking #MONARCH3 study updates at #SABCS2023! Discover how combining abemaciclib with aromatase inhibitors advances treatment for HER2- metastatic breast cancer. 🎥 Full video: medimix.be/onco/the-monar… #BreastCancerResearch #MediMix
#SABCS23 in pillole, secondo @ArmandOrlandi #breastcancer @matteolambe @BianchiniGP #MONARCH3 #NATALEE #monarchE #INAVO120
#SABCS2023 left many of us with hope, optimism but many unanswered questions and controversies! Our podcast covers the 4 following pivotal trial updates #MONARCH3 #INAVO120 #KATHERINE #PREFERABLE-EFFECT open.spotify.com/episode/7zGhjO…
#SABCS23 | Lucia Del Mastro: dal #MONARCH3 conferme su efficacia e impatto clinico dell’impiego di abemaciclib nella paziente con #carcinomamammario HR+, HER2- A breve l’intervista completa 🔜! @matteolambe @SanMartino_Ge
2. #MONARCH3 8 year follow-up: #Abemaciclib + AI vs AI in HR+ mBC 1L: - ITT showed ⬆️of 13.1mos OS with Abema (66.8 vs 53.7 mos) BUT⛔️ statistical significant (HR: 0.804; 95% CI, 0.637-1.015; p=0.0664) 🤔 Now what? - Ribo > Abema > Palbo? 3/6
MONARCH3: Final OS analysis (median fu 8 years) 66.8 vs 53.7 months Not statistically significant but clinically meaningful 🔺13.1 months #bcsm #SABCS23 @OncoAlert
#MONARCH3 Final OS data (median follow up of 8.1 years) OS: 66.8 vs 53.7 months Was not statistically significant even with 13.1 months 🔺 different! To control Arm clinical meaningful improvement ✔️ Is it because of small sample size? 2 ndry endpoint? @OncoAlert #SABCS23
Final analysis of #MONARCH3 trial in patients with advanced endocrine sensitive #BreastCancer: > 1 year OS gain with addition of #abemaciclib to ET but not statistically significant…great to see median OS beyond 5 years also in visceral disease @OncoAlert #bcsm @SABCSSanAntonio
#MONARCH3 trial 1st line abemaciclib in HR+/HER2- aBC Clinically and numerically higher OS 66.8 vs 53.7 months #SABCS23 #abemaciclib @SABCSSanAntonio
Lo studio #MONARCH3 ha mostrato che con #abemaciclib, associato ad un inibitore di aromatasi, c'è un prolungamento della sopravvivenza globale (OS) di 13,1 mesi nelle donne con #carcinomamammario metastatico HR+, HER2. L'articolo: medinews.it/comunicati/tum…
Il #Monarch3 è uno tra i più importanti studi che hanno valutato l’efficacia dei CDK 4/6 inhibitor in un setting di tumore della mammella con recettori ormonali positivi HER2- endocrino sensibili. #breastcancer Ce ne parla @BianchiniGP. 🎙️bit.ly/3PAkC0z
Auch in unserem Live-#Webinar am morgigen Dienstag 20.9. um 17:30 Uhr ist die #MONARCH3-Studie eines der #ESMO22-Highlights von @DLueftner zum #Mammakarzinom. Jetzt anmelden und einen CME-Punkt sammeln: medical-tribune.de/fortbildung/we…
👀 on @OncJournal ➡️ #Safety analysis of #MONARCH2 & #MONARCH3 & management of abemaciclib-associated adverse events ➡️ PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities #Oncoalert theoncologist.onlinelibrary.wiley.com/doi/full/10.10…
DONATING ALL MY MUSIC STREAMING MONEY TO ANY BLM FUNDRAISERS I COME ACROSS ❤️ (link more below) #MONARCH3
#MONARCH3 Final OS data (median follow up of 8.1 years) OS: 66.8 vs 53.7 months Was not statistically significant even with 13.1 months 🔺 different! To control Arm clinical meaningful improvement ✔️ Is it because of small sample size? 2 ndry endpoint? @OncoAlert #SABCS23
1. #MONARCH3 OS update, Ph3, AI Vs #abemaciclib + AI in HR+ve, mBC - Abema improved OS (67.1 mos vs 54.5 mos, HR: 0.754) but not stat. significant (final data in 2023) - Pts with visceral disease did better - Cross trial OS comparison: #Ribociclib +ve & #Palbociclib -ve 2/6
Second interim analysis of OS data from #MONARCH3 at #ESMO22: numerical longer OS with abemaciclib in HR+,HER-neg #breastcancer, that does not cross the statistical significant threshold as per statistical design. Final OS analysis in 2023 @OncoAlert
Dr. Goetz presents IA2 #MONARCH3 OS for AI +/- abema: OS - 54.5 mo vs 67.1 months, p value not signif. OS visceral Mets: ⬆️ 16.3 months w/ abema but again not statistically signif yet. Updated PFS: 14.8 to 29 mo w/ abema Final OS will be reported next year #bcsm #ESMO22
やっぱりTHIE AUDIOはあたたかい。 凄くクリアで解像度高いのに音の繋がりが滑らかでぬくぬく。 低音域は主張しすぎておらず全然支配的ではないのにも関わらず、分離と解像度のお陰でベースの弦の揺れまで聴き取れる。 高音域も伸びる伸びるで聴いてて楽しい。 #THIEAUDIO #Monarch3
Updated results from #MONARCH3 at #ESMO22: addition of #abemaciclib to an aromatase inhibitor improves overall survival in endocrine sensitive advanced #bcsm (not significant at this interim analysis but to me clinically relevant: mOS=67 months, >1y gain) @OncoAlert @myESMO
2. #MONARCH3 8 year follow-up: #Abemaciclib + AI vs AI in HR+ mBC 1L: - ITT showed ⬆️of 13.1mos OS with Abema (66.8 vs 53.7 mos) BUT⛔️ statistical significant (HR: 0.804; 95% CI, 0.637-1.015; p=0.0664) 🤔 Now what? - Ribo > Abema > Palbo? 3/6
MONARCH3: Final OS analysis (median fu 8 years) 66.8 vs 53.7 months Not statistically significant but clinically meaningful 🔺13.1 months #bcsm #SABCS23 @OncoAlert
#MONARCH3 #Abemaciclib #IAnoesteroideo #CoberturaESMO22 #ScienceLink Un análisis provisional de los datos del estudio fase III, MONARCH 3, respalda el uso de abemaciclib + IA no esteroideo en pacientes con cáncer de mama avanzado RH+/HER2-. bit.ly/3x7QSzR
Also true in breast oncology. #MONARCH3 trial of 1L ET+/-abema for metastatic breast cancer. Doubling of PFS, major numerical OS benefit with abema— yet with a clear crossing of the curves. Important to recognize frail patients, which may do well (if not better) with monotherapy.
Same phenomenon occurs in #MARIPOSA as noted by Dr. @harpreet_md in #FLAURA2 - its minor but perhaps early increase toxicity with intensified treatment is bad for some patients outcome? #WCLC2025 #lcsm
Brief report from #MONARCH3 on @Nature_NPJ shows the consistent benefit of adding abema to 1L AI in HR+ mBC patients - with the largest effect observed in subgroups with poor prognostic features nature.com/articles/s4152…
Final analysis of #MONARCH3 trial in patients with advanced endocrine sensitive #BreastCancer: > 1 year OS gain with addition of #abemaciclib to ET but not statistically significant…great to see median OS beyond 5 years also in visceral disease @OncoAlert #bcsm @SABCSSanAntonio
Check out this podcast to hear updates from @JAMouabbi on #SABCS23! Dr. Mouabbi delves into the presentations on the #HER2CLIMB02, #MONARCH3, and #INAVO trials and explains their potentials to impact the #BreastCancer treatment landscape. Listen here! oncdata.com/news/highlight…
Something went wrong.
Something went wrong.
United States Trends
- 1. Sonny Gray 5,720 posts
- 2. Dick Fitts N/A
- 3. #yummymeets N/A
- 4. Red Sox 6,186 posts
- 5. Clarke 6,026 posts
- 6. #GMMTV2026 4.09M posts
- 7. National Treasure 4,574 posts
- 8. Giolito N/A
- 9. Thankful 51.3K posts
- 10. Gone in 60 1,588 posts
- 11. Happy Thanksgiving 20.4K posts
- 12. Breslow N/A
- 13. Joe Ryan N/A
- 14. Raising Arizona N/A
- 15. Chaim 1,085 posts
- 16. Chuck and Nancy 1,994 posts
- 17. #csm221 4,869 posts
- 18. Academic All-District N/A
- 19. Ghost Rider 1,892 posts
- 20. Mark Kelly 254K posts